To construct a recombinant eukaryotic expression plasmid of microRNA let7a2 and express it in lung cancer A549 cells. Methodslet7a2 precursor sequence was amplified by RTPCR using RNA from A549 cells and was cloned into the pSilencer4.1 CMV neoexpression vector to produce the recombinant pSilencer4.1let7a2. Then the recombinant pSilencer4.1let7a2 was transfected into lung cancer A549 cells, and the prelet7a2 expression was verified by RTPCR. According to the miRBase Targets database, the target sequence of let7a2 was synthesized and inserted to the pMIRReport luciferase reporter vector to construct pMIRReportlet7a2T, which was cotransfected with pSilencer4.1let7a2 into A549 cells, and the relative luciferase activity was detected. The effect of let7a2 on A549 cell proliferation was tested by MTT. ResultsThe results of DNA sequencing showed that sequences of pMIRReportlet7a2T and pSilencer5.1let7a2 were correct. RTPCR prelet7a2 was overexpressed in A549 cells after transfection of pSilencer4.1let7a2. Cotransfection of pSilencer4.1let7a2 and pMIRReportlet7a2T showed that mature let7a2 had biological activity. MTT results indicated that let7a2 inhibited proliferation of the transfected A549 cells. ConclusionThe eukaryotic expression plasmid of let7a2 was successfully constructed and effectively expressed in A549 cells.